HPCM
NVO

Hunter Perkins Capital Management’s Novo Nordisk NVO Stock Holding History

Hunter Perkins Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,000
Closed -$223K – 97
2022
Q2 		$223K Buy
+4,000
New +$222K 0.05% 77

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Hunter Perkins Capital Management's NVO Position: Q3 2022 in Review

Hunter Perkins Capital Management sold out of Novo Nordisk (NVO) in Q3 2022, closing a stake of 4,000 shares — an estimated $223K sold.

Hunter Perkins Capital Management first reported a position in NVO in Q2 2022 and held it in 1 quarter. The position peaked at $223K in Q2 2022. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

  • Hunter Perkins Capital Management reported no remaining Novo Nordisk position as of Q3 2022 after selling out during the quarter.
  • Hunter Perkins Capital Management sold 4,000 Novo Nordisk shares in Q3 2022, an estimated $223K.
  • Hunter Perkins Capital Management first reported a position in Novo Nordisk in Q2 2022 and held it in 1 quarter.
  • Hunter Perkins Capital Management's Novo Nordisk position peaked at $223K in Q2 2022.
  • 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Hunter Perkins Capital Management's 13F filing for Q3 2022, filed 13 Oct 2022.